YOLO: SELLAS Life Sciences (SLS): why I’m bullish on GPS and watching ASH in December
Author is long ~5000 shares of SELLAS Life Sciences bullish on galinpepimut-S (GPS), a therapeutic cancer vaccine for AML, based on patients continuing treatment years post-initial dosing and an approaching Phase 3 survival analysis of REGAL trial. Secondary catalyst is SLS009, a CDK9 inhibitor showing 46% response rate in relapsed/refractory AML, with additional data expected Q4 2026 and potential ASH presentation in December 2026.
At post $11.65·Now $10.72-8.0% since postedas of Oct 19, 11:31 AM ET
1d—
3d+2.4%
1w-14.3%
1m—
3m—
6m—
1y—
Long 82,500 shares of SLS
Long SLS $18C exp Sep 20 · 425 contracts
$48k —> $622k on SLS
Pre-revenue biotech with transformative potential. Author holds 82,500 shares and 425 September $18 calls, expecting $50–$100 end-of-year price target, betting on near-term catalyst and significant upside.
At post $14.33·Now $10.72-25.2% since postedas of Oct 19, 11:31 AM ET
1d—
3d-4.2%
1w-7.8%
1m-16.1%
3m—
6m—
1y—
Million dollar SLS yolo (two slides)
Author has held conviction in SLS since December 8th based on belief in the company's science and continues buying dips ahead of data catalysts. The position has grown to near $1M, demonstrating sustained conviction.
At post $10.84·Now $10.72-1.1% since postedas of Oct 19, 11:31 AM ET
1d—
3d-6.9%
1w-7.6%
1m+32.3%
3m—
6m—
1y—
“holding until 1 mil”
SLS holding until I have 1 mil. Thoughts
Author is holding SLS stock with conviction until reaching $1M in gains, indicating a bullish directional view and long-term commitment to the position.
At post $15.45·Now $10.72-30.6% since postedas of Oct 19, 11:31 AM ET
1d—
3d-14.1%
1w-3.0%
1m-34.7%
3m-24.9%
6m—
1y—
Here is what can still fail the SLS trial when success seems "guaranteed"
Author, a biomedicine professor, models the SLS trial using conservative Weibull methodology and estimates an 80% probability of success, 15% narrow miss, and 5% failure. Despite not being mathematically guaranteed, the expected upside from trial success and potential regulatory approvals justify current valuation; author holds 1799 shares.
At post $8.33·Now $10.72+28.7% since postedas of Oct 19, 11:31 AM ET
1d-1.7%
3d-1.2%
1w-7.8%
1m+79.8%
3m+60.1%
6m—
1y—
Space is the place, man
SLS is positioned for very positive trial readout results in the coming months with 78 of 80 events reached. Author expects positive results and a potential buyout within the next year.
At post $7.78·Now $10.72+37.8% since postedas of Oct 19, 11:31 AM ET
1d—
3d—
1w+19.7%
1m+3.5%
3m+72.2%
6m—
1y—
“full port, mix of call options with varying expirations (referenced leaps and closer-dated positions, screenshot shown but specific strikes/dates not legible in text)”
All in on cancer $SLS
SLS's GPS drug REGAL trial is near completion (78/80 events) and the author expects a positive outcome based on strong Phase 2 CR2 AML data showing 16.3 months vs 5.4 months median overall survival. Author is fully committed to the position, betting the trial success will drive stock sharply higher.
At post $8.97·Now $10.72+19.5% since postedas of Oct 19, 11:31 AM ET
1d-15.7%
3d-13.3%
1w-4.3%
1m-10.3%
3m+46.0%
6m—
1y—
“LEAPS”
Options changed my life pt.5
SLS offers a high-risk, high-reward opportunity with potential 20x upside using LEAPS, representing a speculative bet on the company's success with binary outcome.
At post $5.01·Now $10.72+114.0% since postedas of Oct 19, 11:31 AM ET
1d—
3d+4.8%
1w+41.3%
1m+64.3%
3m+133.5%
6m—
1y—
“Own 809K shares here (and am continuously accumulating every week)”
$SLS (Deepest Due Diligence for SLS-009, Machine Learning Models and Results, and Buyout Deep DD) (From a Deep Value Investor)
Author, a large shareholder with 809K shares and deep statistical analysis, built a 16-model ML ensemble predicting SLS-009 (Tambiciclib) Phase 2B trial in AML will achieve 64.4% ORR and 61.1% CR/CRi, well above FDA accelerated approval thresholds. Combined with GPS/REGAL having >99% success probability, acquisition by a large pharma could value the complete AML patient journey very highly.
At post $5.04·Now $10.72+112.7% since postedas of Oct 19, 11:31 AM ET
1d-1.8%
3d-5.6%
1w-0.8%
1m-2.2%
3m+53.4%
6m+129.2%
1y—
Long 805,000 shares of SLS
$SLS Part 2 and FINAL (Deepest Due Diligence for REGAL Trial) (From a Deep Value Investor) (Predicting BAT mOS from Predictive Model)
The author, employing a constrained parametric mixture-cure model and Bayesian evidence synthesis, predicts the control arm (BAT) median overall survival at 11.4 months with 91% accuracy. This produces an expected hazard ratio of 0.35–0.50 for the GPS vaccine arm, far exceeding the trial threshold of 0.636, with modeled trial success probability of 99.9%. The rare asymmetric opportunity reflects an exceptionally high margin of safety.
At post $4.04·Now $10.72+165.3% since postedas of Oct 19, 11:31 AM ET
1d+2.7%
3d+2.7%
1w+21.8%
1m+17.8%
3m+122.0%
6m+224.3%
1y—
Long 805,000 shares of SLS
$SLS (Deepest Due Diligence for REGAL Trial) (From a Deep Value Investor)
REGAL Phase 3 trial data shows deceleration in mortality events (72 of 80 required by month 58, only 12 deaths in past 12 months from 66 at risk), indicating a cure-fraction model with ~42-48% of GPS arm patients achieving durable remission. Author's model predicts hazard ratio of 0.35-0.50 (well below 0.636 threshold), positioning GPS as potential new standard of care in AML CR2 with 5-8 year monopoly.
At post $3.66·Now $10.72+192.9% since postedas of Oct 19, 11:31 AM ET
1d—
3d+3.6%
1w+13.4%
1m+37.7%
3m+93.4%
6m+249.2%
1y—
SELLAS Life Sciences (SLS) - Deep Dive DD on GPS and the REGAL trial
Author has conducted comprehensive research on SLS's GPS and REGAL trial catalysts and believes the opportunity merits investment. The detailed DD article serves as a resource for evaluating the company's potential.
At post $3.81·Now $10.72+181.4% since postedas of Oct 19, 11:31 AM ET
1d—
3d-1.3%
1w-5.8%
1m+56.4%
3m+31.5%
6m+207.1%
1y—
DD: SLS to $100+: The "New Math" Moonshot
SELLAS Life Sciences is approaching a critical window for its Phase 3 REGAL trial with delayed event rates suggesting the GPS drug arm significantly extends survival. The FDA's new January 2026 Bayesian guidance allows early superiority stopping without hitting 80 deaths, and a February superiority call could trigger M&A interest from Merck seeking bolt-on oncology assets, with acquisition valuations potentially reaching $100+ per share.
At post $4.40·Now $10.72+143.6% since postedas of Oct 19, 11:31 AM ET
1d-9.8%
3d-14.3%
1w-5.5%
1m+11.8%
3m+10.9%
6m+157.3%
1y—
$SLSr/pennystocks🚩SUSPICIOUS POST🚩bullish u/Yung_Ceejay · 281d ago1 prior · awaiting results SLS - hype, manipulation, lies, schemes…
SLS has been subjected to coordinated manipulation by hedge funds through naked shorting and dilution following positive catalysts, but institutional ownership is rising and recent prolonged survival data supports the underlying science. Shorts resorting to misinformation and covering failures suggest the stock is undervalued and positioned for recovery as bigger institutional players enter.
At post $4.11·Now $10.72+160.8% since postedas of Oct 19, 11:31 AM ET
1d—
3d0.0%
1w-3.2%
1m-8.5%
3m+15.8%
6m+210.5%
1y—
SLS Part II – Follow-up: from “discounted entry” to early re-rating (and we are still early)
SELLAS is undergoing a structural re-rating driven by clinical trial math, not hype. The Phase 3 REGAL trial is showing prolonged survival indicators (72/80 events with median OS exceeding 13.5 months in a disease with historical 6-8 month survival), while the CDK9 inhibitor SLS009 provides a second value driver. The platform oncology company transition, combined with strong cash position extending to 2027, positions SLS for significant upside as catalysts converge.
At post $5.00·Now $10.72+114.4% since postedas of Oct 19, 11:31 AM ET
1d-18.0%
3d-22.8%
1w-17.8%
1m-23.6%
3m-17.4%
6m+199.6%
1y—
$SLSr/pennystocks🚩SUSPICIOUS POST🚩bullish u/Yung_Ceejay · 291d ago1 prior · awaiting results Sellas Lifesciences - Cancer Moonshot in the process of squeezing! Hand written DD!
Sellas has two first-in-class multi-cancer drugs with de-risked pipelines showing strong clinical survival benefits. The lead asset GPS demonstrated unprecedented 13.5+ month median survival in AML patients versus 8 months expected, coupled with high short interest and favorable technical setup suggesting significant upside potential.
At post $4.35·Now $10.72+146.4% since postedas of Oct 19, 11:31 AM ET
1d—
3d—
1w-11.3%
1m-13.3%
3m-3.2%
6m+239.3%
1y—
SELLAS Life Sciences (SLS): A Late-Stage Biotech Entering the Final Phase and the Market Is Starting to Notice
SELLAS is a late-stage biotech with a pivotal Phase 3 survival trial (REGAL) nearing completion (72 of 80 events) in a high-unmet-need AML setting, showing constructive safety signals and slowing event rates suggesting better patient survival than modeled. At current sub-$4 share price and $525M market cap, the stock is undervalued relative to probability-weighted outcomes of clinical success and strategic M&A, with a realistic valuation range of $5–12B+ supporting significant upside.
At post $3.31·Now $10.72+223.9% since postedas of Oct 19, 11:31 AM ET
1d+13.9%
3d+31.4%
1w+23.9%
1m+17.5%
3m+21.1%
6m+274.3%
1y—
$SLS on the verge of a massive break out
SLS has a phase 3 immunotherapy vaccine (GPS) for AML with positive interim data showing 13.5-month median survival, pending results this month that could unlock $4-6 billion in value for a current $300 million market cap. Strong institutional ownership and insider buying support upside if phase 3 results are positive.
At post $2.11·Now $10.72+408.1% since postedas of Oct 19, 11:31 AM ET
1d+10.9%
3d+11.8%
1w+34.6%
1m+88.6%
3m+138.9%
6m+266.4%
1y—
$SLS Is The Best Stock For Monday, Here's Why:
SELLAS has a strengthened pipeline with promising phase 3 and phase 2 cancer drug candidates, solid clinical efficacy data, and major trial readouts expected through December that could drive upside. The improved cash position de-risks execution.
At post $1.82·Now $10.72+489.0% since postedas of Oct 19, 11:31 AM ET
1d—
3d+7.7%
1w+11.5%
1m+125.3%
3m+203.8%
6m+352.2%
1y—
$SLSr/pennystocksDDbullish u/ysh1324 · 317d agono track record yet SLS ($1.75) - Phase 3 AML Trial Readout by Year-End: Hype Building for a Potential 4x-5x Runner? Full DD on Sellas Life Sciences
Sellas Life Sciences is developing GPS vaccine and SLS009 inhibitor for AML. Phase 3 REGAL readout expected by year-end with survival data (23 vs. 11 months in Phase 2); positive results could trigger FDA filing and 2-5x upside. Near-term ASH conference data presentation (early Phase 2 results) offers additional catalyst.
At post $1.82·Now $10.72+489.0% since postedas of Oct 19, 11:31 AM ET
1d—
3d+4.4%
1w+11.5%
1m+174.7%
3m+203.8%
6m+396.7%
1y—